Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC von Knox, J.J., Barrios, C.H., Kim, T.M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S.Y., Flaig, T.W., Page, R.D., Beck, J.T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R.J.

Volltext

Proton Beam Therapy Utilization and Disparity in the United States for Treatment of Localized Prostate Cancer: A Study of the National Cancer Data Base von Amini, A, Kavanagh, B.D, Raben, D, Crawford, E.D, Flaig, T.W, Kessler, E.R, Lam, E.T, Maroni, P, Pugh, T.J

Volltext

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL von Graff, J.N., Baciarello, G., Armstrong, A.J., Higano, C.S., Iversen, P., Flaig, T.W., Forer, D., Parli, T., Phung, D., Tombal, B., Beer, T.M., Sternberg, C.N.

Volltext

Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone... von Fizazi, K., Flaig, T.W., Stöckle, M., Scher, H.I., de Bono, J.S., Rathkopf, D.E., Ryan, C.J., Kheoh, T., Li, J., Todd, M.B., Griffin, T.W., Molina, A., Ohlmann, C.H.

Volltext

2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC) von Sridhar, S., O'Donnell, P.H., Flaig, T.W., Rosenberg, J.E., Hoimes, C.J., Milowsky, M.I., Srinivas, S., George, S., McKay, R.R., Petrylak, D.P., Coelho Barata, P.M., Hwang, C., Cruz-Correa, M., Iafolla, M., Mckean, M., Dreicer, R., Brancato, S., Lukas, J.J., Yu, Y., Moon, H.

Volltext

Organ Preservation for Muscle-Invasive Squamous Cell Carcinoma of the Urinary Bladder in the United States von Stokes, W.A., Kessler, E.R., Wilson, S., Lam, E.T., Flaig, T.W., Kavanagh, B.D., Pugh, T.J.

Volltext

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer von Goodman, O B, Flaig, T W, Molina, A, Mulders, P F A, Fizazi, K, Suttmann, H, Li, J, Kheoh, T, de Bono, J S, Scher, H I

Volltext

584P Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant... von Oudard, S.M., Bevans, K.B., Attard, G., Efstathiou, E., Flaig, T.W., Franke, F.A., Goodman, O.B., De Giorgi, U., Pieczonka, C.M., Yeruva, K., De Porre, P., Brookman-May, S.D., Dibaj, S., Wu, D., Mundle, S.D., McCarthy, S., Steuber, T., Suzuki, H., Rathkopf, D.E., Saad, F.

Volltext

Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abirateron... von Kessler, E.R., Gao, D., Flaig, T.W., Breaker, K., Wold, M., Wacker, M., Lam, E.T.

Volltext

Corrections to Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in... von Knox, J.J., Barrios, C.H., Kim, T.M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S.Y., Flaig, T.W., Page, R.D., Beck, J.T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R.J.

Volltext

204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study von Flaig, T.W, Curti, B.D, Gordon, M.S, Van Veldhuizen, P.J, Miller, W.H, Ernstoff, M.S, Bhatia, S, Hunder, N.H, Royer, N, Thompson, J.A

Volltext

863 Low dose GTx-758 decreases free testosterone to levels similar to orchiectomy in men with metastatic castration resistant prostate cancer (mCRPC) von Getzenberg, R.H, Yu, E.Y, Smith, J.A, Hancock, M.L, Tutrone, R, Flaig, T.W, Westenfelder, K.R, Szucs, M, Dalton, J.T, Steiner, M.S

Volltext

556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors... von Mulders, P.F.A, Smith, M.R, Fizazi, K, Saad, F, Sternberg, C.N, Miller, K, Logothetis, C.J, Shore, N.D, Small, E.J, Carles, J, Flaig, T.W, Taplin, M-E, Higano, C.S, De Souza, P, De Bono, J.S, Griffin, T.W, De Porre, P, Yu, M.K, Park, Y.C, Li, J, Kheoh, T, Naini, V, Molina, A, Rathkopf, D.E, Ryan, C.J

Volltext

105 Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCR... von Suttmann, H, Mulders, P.F.A, Molina, A, Goodman, O.B, Flaig, T.W, Li, J, Kheoh, T, De Bono, J.S, Scher, H.I

Volltext

Prostate: a study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer von Flaig, T.W, Glode, M, Gustafson, D

Volltext

Tivozanib: practical implications for renal cell carcinoma and other solid tumors von Berge, E M, Bowles, D W, Flaig, T W, Lam, E T, Jimeno, A

Volltext

Axitinib, a new therapeutic option in renal cell carcinoma von Kessler, E R, Bowles, D W, Flaig, T W, Lam, E T, Jimeno, A

Volltext

864 Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)? An analys... von Stöckle, M, Flaig, T, Ohlmann, C.H, Scher, H.I, De Bono, J.S, Rathkopf, D, Ryan, C.J, Kheoh, T, Li, J, Todd, M, Griffin, T.W, Molina, A, Fizazi, K

Volltext